{"id":53236,"date":"2026-01-07T21:02:25","date_gmt":"2026-01-07T13:02:25","guid":{"rendered":"https:\/\/flcube.com\/?p=53236"},"modified":"2026-01-07T21:02:26","modified_gmt":"2026-01-07T13:02:26","slug":"takeda-and-protagonist-submit-rusfertide-nda-for-polycythemia-vera","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53236","title":{"rendered":"Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera"},"content":{"rendered":"\n<p><strong>Takeda Pharmaceutical Company Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4502:TYO\">TYO: 4502<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/TAK:NYSE\">NYSE: TAK<\/a>) and <strong>Protagonist Therapeutics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PTGX:NASDAQ\">NASDAQ: PTGX<\/a>) announced the submission of a <strong>New Drug Application (NDA)<\/strong> to the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for <strong>rusfertide<\/strong>, an investigational <strong>first\u2011in\u2011class subcutaneous hepcidin mimetic peptide<\/strong>, for the treatment of <strong>adults with polycythemia vera (PV)<\/strong>. The filing is supported by positive data from the <strong>Phase\u202f3 VERIFY study<\/strong> and <strong>Phase\u202f2 REVIVE study<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-deal-overview\">Regulatory &amp; Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Rusfertide (subcutaneous hepcidin mimetic peptide)<\/td><\/tr><tr><td><strong>Companies<\/strong><\/td><td>Takeda (NYSE: TAK), Protagonist Therapeutics (NASDAQ: PTGX)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NDA submitted to FDA<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adults with polycythemia vera (PV)<\/td><\/tr><tr><td><strong>FDA Designations<\/strong><\/td><td>Breakthrough Therapy, Orphan Drug, Fast Track<\/td><\/tr><tr><td><strong>Clinical Basis<\/strong><\/td><td>Phase\u202f3 VERIFY (NCT05210790) and Phase\u202f2 REVIVE (NCT04057040)<\/td><\/tr><tr><td><strong>Deal Structure<\/strong><\/td><td>Takeda secured 50% US rights and ex\u2011US rights for USD\u202f300\u202fM upfront (2024)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<p><strong>Rusfertide<\/strong> is a <strong>first\u2011in\u2011class subcutaneously administered hepcidin mimetic peptide<\/strong> designed to <strong>regulate iron homeostasis and red blood cell production<\/strong>, thereby controlling <strong>hematocrit levels<\/strong> in PV patients.<\/p>\n\n\n\n<p><strong>Key Features<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Mimics <strong>hepcidin<\/strong> to suppress <strong>iron availability<\/strong> and <strong>erythropoiesis<\/strong><\/li>\n\n\n\n<li><strong>Administration<\/strong>: <strong>Subcutaneous injection<\/strong> (patient\u2011friendly vs. phlebotomy)<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: <strong>Only therapy targeting iron\u2011dependent pathway<\/strong> in PV; potential <strong>disease\u2011modifying<\/strong> effect<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence\">Clinical Evidence<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-phase-3-verify-study-nct05210790\">Phase\u202f3 VERIFY Study (NCT05210790)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Design<\/strong>: Global, randomized, placebo\u2011controlled 32\u2011week primary analysis, 52\u2011week extended results<\/li>\n\n\n\n<li><strong>Primary Endpoint<\/strong>: <strong>Met<\/strong> \u2013 Substantially higher response rate vs. placebo + standard of care<\/li>\n\n\n\n<li><strong>Key Secondary Endpoints<\/strong>: <strong>All four met<\/strong><\/li>\n\n\n\n<li>Durable hematocrit control<\/li>\n\n\n\n<li>Reduction in phlebotomy requirements<\/li>\n\n\n\n<li>Improvement in pre\u2011specified patient\u2011reported outcomes (PROs)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-phase-2-revive-study-nct04057040\">Phase\u202f2 REVIVE Study (NCT04057040)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Design<\/strong>: Randomized, placebo\u2011controlled<\/li>\n\n\n\n<li><strong>Results<\/strong>: Supported VERIFY findings, demonstrating <strong>consistent efficacy and safety<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Significance<\/strong>: First therapy to show <strong>durable hematocrit control<\/strong> and <strong>PRO improvement<\/strong> in PV, addressing <strong>unmet need<\/strong> beyond phlebotomy and cytoreductive agents.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p><strong>Polycythemia Vera Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>U.S. Prevalence<\/strong>: <strong>~100,000<\/strong> patients diagnosed; <strong>40\u201150%<\/strong> inadequately controlled on current therapy<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: <strong>Ruxolitinib<\/strong> only approved second\u2011line; <strong>hydroxyurea<\/strong> standard first\u2011line has <strong>toxicity limitations<\/strong><\/li>\n\n\n\n<li><strong>Market Size<\/strong>: <strong>U.S. PV market<\/strong> valued at <strong>$800\u202fmillion<\/strong> (2025), growing at <strong>10% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Rusfertide Peak Sales<\/strong>: <strong>$1.2\u20111.5\u202fbillion<\/strong> potential (U.S. + ex\u2011U.S.) by 2030<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Limitation<\/th><\/tr><\/thead><tbody><tr><td><strong>Rusfertide<\/strong><\/td><td><strong>Takeda\/Protagonist<\/strong><\/td><td>Hepcidin mimetic<\/td><td><strong>NDA submitted<\/strong><\/td><td>First\u2011in\u2011class<\/td><\/tr><tr><td><strong>Ruxolitinib<\/strong><\/td><td>Incyte\/Novartis<\/td><td>JAK1\/2 inhibitor<\/td><td>Marketed (2L)<\/td><td>Anemia, thrombocytopenia<\/td><\/tr><tr><td><strong>Hydroxyurea<\/strong><\/td><td>Generic<\/td><td>Chemotherapy (cytoreduction)<\/td><td>Standard 1L<\/td><td>Myelosuppression, AML risk<\/td><\/tr><tr><td><strong>Peginterferon alfa<\/strong><\/td><td>Generic<\/td><td>Immunomodulator<\/td><td>Alternative<\/td><td>Flu\u2011like symptoms, depression<\/td><\/tr><tr><td><strong>Bomedemstat<\/strong><\/td><td>Imago BioSciences<\/td><td>LSD1 inhibitor<\/td><td>Phase\u202fIII<\/td><td>Early\u2011stage competitor<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Moat<\/strong>: Rusfertide\u2019s <strong>novel mechanism<\/strong> and <strong>superior safety<\/strong> create <strong>7\u201110 year exclusivity<\/strong> via orphan drug and breakthrough designations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<p><strong>For Protagonist<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront<\/strong>: USD\u202f300\u202fM (received 2024)<\/li>\n\n\n\n<li><strong>Milestone Potential<\/strong>: Up to <strong>USD\u202f900\u202fM<\/strong> (regulatory + commercial)<\/li>\n\n\n\n<li><strong>Royalties<\/strong>: <strong>Mid\u2011teens<\/strong> on ex\u2011U.S. sales; <strong>low\u2011double\u2011digit<\/strong> on U.S. sales (50% share)<\/li>\n<\/ul>\n\n\n\n<p><strong>For Takeda<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Investment<\/strong>: USD\u202f300\u202fM upfront + shared development costs<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong>: <strong>USD\u202f600\u2011750\u202fM<\/strong> peak share (U.S. + ex\u2011U.S.)<\/li>\n\n\n\n<li><strong>Portfolio Synergy<\/strong>: Complements <strong>mobocertinib<\/strong> (lung cancer) and <strong>TAK\u2011755<\/strong> (hereditary angioedema) in rare disease franchise<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding rusfertide\u2019s FDA approval timeline, market penetration, revenue forecasts, and competitive positioning. Actual results may differ materially due to regulatory review outcomes, commercial execution, and competitive dynamics in the myeloproliferative neoplasm market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) and Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[38,4534,874,1565,345,1141],"class_list":["post-53236","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-market-approval-filings","tag-nasdaq-ptgx","tag-nyse-tak","tag-protagonist-therapeutics","tag-takeda","tag-tyo-4502"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) and Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for rusfertide, an investigational first\u2011in\u2011class subcutaneous hepcidin mimetic peptide, for the treatment of adults with polycythemia vera (PV). The filing is supported by positive data from the Phase\u202f3 VERIFY study and Phase\u202f2 REVIVE study.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53236\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera\" \/>\n<meta property=\"og:description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) and Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for rusfertide, an investigational first\u2011in\u2011class subcutaneous hepcidin mimetic peptide, for the treatment of adults with polycythemia vera (PV). The filing is supported by positive data from the Phase\u202f3 VERIFY study and Phase\u202f2 REVIVE study.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53236\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T13:02:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-07T13:02:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53236#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53236\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera\",\"datePublished\":\"2026-01-07T13:02:25+00:00\",\"dateModified\":\"2026-01-07T13:02:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53236\"},\"wordCount\":527,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Market approval filings\",\"NASDAQ: PTGX\",\"NYSE: TAK\",\"Protagonist Therapeutics\",\"Takeda\",\"TYO: 4502\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53236#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53236\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53236\",\"name\":\"Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-07T13:02:25+00:00\",\"dateModified\":\"2026-01-07T13:02:26+00:00\",\"description\":\"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) and Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for rusfertide, an investigational first\u2011in\u2011class subcutaneous hepcidin mimetic peptide, for the treatment of adults with polycythemia vera (PV). The filing is supported by positive data from the Phase\u202f3 VERIFY study and Phase\u202f2 REVIVE study.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53236#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53236\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53236#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera - Insight, China&#039;s Pharmaceutical Industry","description":"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) and Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for rusfertide, an investigational first\u2011in\u2011class subcutaneous hepcidin mimetic peptide, for the treatment of adults with polycythemia vera (PV). The filing is supported by positive data from the Phase\u202f3 VERIFY study and Phase\u202f2 REVIVE study.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53236","og_locale":"en_US","og_type":"article","og_title":"Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera","og_description":"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) and Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for rusfertide, an investigational first\u2011in\u2011class subcutaneous hepcidin mimetic peptide, for the treatment of adults with polycythemia vera (PV). The filing is supported by positive data from the Phase\u202f3 VERIFY study and Phase\u202f2 REVIVE study.","og_url":"https:\/\/flcube.com\/?p=53236","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-07T13:02:25+00:00","article_modified_time":"2026-01-07T13:02:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53236#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53236"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera","datePublished":"2026-01-07T13:02:25+00:00","dateModified":"2026-01-07T13:02:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53236"},"wordCount":527,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Market approval filings","NASDAQ: PTGX","NYSE: TAK","Protagonist Therapeutics","Takeda","TYO: 4502"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53236#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53236","url":"https:\/\/flcube.com\/?p=53236","name":"Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-07T13:02:25+00:00","dateModified":"2026-01-07T13:02:26+00:00","description":"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) and Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for rusfertide, an investigational first\u2011in\u2011class subcutaneous hepcidin mimetic peptide, for the treatment of adults with polycythemia vera (PV). The filing is supported by positive data from the Phase\u202f3 VERIFY study and Phase\u202f2 REVIVE study.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53236#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53236"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53236#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53236"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53236\/revisions"}],"predecessor-version":[{"id":53237,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53236\/revisions\/53237"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}